Skip to main content
NIH funding notice RFA-MH-21-226

Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional)

Closed on August 27, 2021.

Posted
May 24, 2021
Close date
August 27, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
2
2 new
Median first-year cost
$214,500
$429,000 in all
Institutions
2
2 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. UNIVERSITY OF ALABAMA AT BIRMINGHAM1
  2. UNIVERSITY OF SOUTHERN CALIFORNIA1

Most frequent study sections

  1. Special Emphasis Panel (ZMH1 ERB-G (03))2
2 awards under RFA-MH-21-226 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2022Eradication of brain/CNS HIV reservoirs via anti-HIV gene-modified macrophages1R21MH130183-01Kamata, MasakazuUNIVERSITY OF ALABAMA AT BIRMINGHAM, ALFirst-year cost $222,750Study section ZMH1
FY2022Gene edited B cells to co-express CNS-targeted antibodies1R21MH130178-01Cannon, Paula MUNIVERSITY OF SOUTHERN CALIFORNIA, CAFirst-year cost $206,250Study section ZMH1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-12-0.3.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.

RFA-MH-21-226: Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R21 Clinical Trial Optional) | ScienceDex | ConductScience